Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer
- 13 March 2021
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 70 (10) , 2937-2950
Abstract
Immunosurveillance and immunoscavenging prompted by preoperative chemoradiotherapy (CCRT) may contribute to improve local control and increase survival outcomes for patients with locally advanced rectal cancer (LARC). In this study, we investigated several genotypes of pattern recognition receptors (PRRs) and their impact on therapeutic efficacy in LARC patients treated with CCRT. We found that homozygosis of formyl peptide receptor 1 (FPR1) (E346A/rs867228) was associated with reduced 5-year overall survival (OS) by Kaplan–Meier analysis (62% vs. 81%, p = 0.014) and multivariate analysis [hazard ratio (HR) = 3.383, 95% CI = 1.374–10.239, p = 0.007]. Moreover, in an animal model, we discovered that the FPR1 antagonist, Boc-MLF (Boc-1), reduced CCRT therapeutic efficacy and decreased cytotoxic T cells and T effector memory cells after chemoradiotherapy treatment. Pharmacologic inhibition of FPR1 by Boc-1 decreased T lymphocyte migration to irradiated tumor cells. Therefore, these results revealed that the FPR1 genotype participates in CCRT-elicited anticancer immunity by reducing T lymphocytes migration and infiltration, and that the FPR1-E346A CC genotype can be considered an independent biomarker for chemo- and radiotherapy outcomes.Keywords
Funding Information
- Health and welfare surcharge of tobacco products (MOHW109-TDU-B-212-134024)
- Ministry of Science and Technology (MOST106-2314-B-039-005)
- Ministry of Science and Technology, Taiwan (MOST107-2314-B-039-027-MY3, MOST107-2314-B-039-057-MY3)
This publication has 41 references indexed in Scilit:
- Patterns of failure in patients with locally advanced rectal cancer receiving pre-operative or post-operative chemoradiotherapyRadiation Oncology, 2013
- Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 YearsJournal of Clinical Oncology, 2012
- Relevance of long-lived CD8+ T effector memory cells for protective immunity elicited by heterologous prime-boost vaccinationFrontiers in Immunology, 2012
- Frontiers in NephrologyJournal of the American Society of Nephrology, 2007
- Effector Memory T Cells, Early Metastasis, and Survival in Colorectal CancerNew England Journal of Medicine, 2005
- Prognostic Significance of Tumor Regression After Preoperative Chemoradiotherapy for Rectal CancerJournal of Clinical Oncology, 2005
- Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapyInternational Journal of Colorectal Disease, 2005
- A cell line model for the differentiation of human dendritic cellsBiochemical and Biophysical Research Communications, 2005
- Preoperative versus Postoperative Chemoradiotherapy for Rectal CancerNew England Journal of Medicine, 2004
- Functional differences between human formyl peptide receptor isoforms 26, 98, and G6Naunyn-Schmiedeberg's Archives of Pharmacology, 2003